 Bionic Sight, LLC announced today that it has dosed the first patient in the Companys Phase 12 clinical trial of BS01, an optogenetic gene therapy for patients with Retinitis Pigmentosa. This is an important step toward bringing BS01 forward as a treatment to enable patients with retinal degenerative diseases to detect light, motion, and shapes, with the ultimate goal of restoring eyesight. Optogenetic proteins act essentially as converters; they receive light and convert it into neural signals. 